Asep

Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis

Retrieved on: 
Tuesday, February 27, 2024
Asep, Incidence, Sepsis, UBC, Medical director, American Medical Association, JAMA, Abdominal pain, Biomarker, Gene expression, Appendectomy, Patent, Appendicitis, Patient, Journal, Data analysis, Pediatrics, Diagnosis, Mortality, Gene expression profiling, Vaccine

VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.

Key Points: 
  • VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
  • The study found that the "diagnostic study of 71 patients with pediatric appendicitis using systems immunology methods revealed a mechanistic understanding of severe disease, indicating immune dysregulation similar to that observed in sepsis.
  • The study concluded that early diagnostics and management strategies for pediatric PA should be informed by underlying immune dysregulation and similarities to sepsis.
  • Based on the new potential benefits of this ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER."

Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc.

Retrieved on: 
Wednesday, November 22, 2023
Medicine, FSE, CSE, Transaction, End-user license agreement, Meta-analysis, Mortality, Septic shock, BioMed Central, Sepsis, PCR, Strategic planning, Side letter, Warrant, Death, RMB, License, Emergency medicine, ASEP, JV, Patent, Security (finance), Asep

VANCOUVER, BC, Nov. 21, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that, through its subsidiary Sepset Biosciences Inc. ("Sepset"), it has signed a definitive joint venture agreement (the "JV Agreement") with leading Chinese medical diagnostic company, Sansure Biotech Inc. ("Sansure"), through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. (the "Sansure Fund").

Key Points: 
  • VANCOUVER, BC, Nov. 21, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that, through its subsidiary Sepset Biosciences Inc. ("Sepset"), it has signed a definitive joint venture agreement (the "JV Agreement") with leading Chinese medical diagnostic company, Sansure Biotech Inc. ("Sansure"), through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. (the "Sansure Fund").
  • Sansure Fund is an investment fund formed by Sansure, Changsha Sanway Spring Venture Capital CO., Ltd. ("Sanway Spring") and certain other investors.
  • Formal registration of SepSMART with the applicable regulatory body in China is a condition precedent of the JV Agreement.
  • We look forward to collaborating with the Sansure team as we bring this technology to market in China."

Asep Inc. Founder, Chair and CEO, Dr. Robert E. W. Hancock, Ranked 4th Best Microbiologist in the World

Retrieved on: 
Tuesday, June 20, 2023
Plan, ASEP, CSE, RSU, Canadian Securities Exchange, Sepsis, Share (finance), Quality of life, FSE, NAI, Research, Sale, Invention, Asep, National academy, Publication, Option, National Academy of Inventors, SEDAR, Fellow, Economic development, Knowledge, Diagnosis, News, Chair, Pharmaceutical industry

In addition to the research.com honour, Dr. Hancock was also installed as a Fellow of the National Academy of Inventors (NAI) based in Tampa, Florida.

Key Points: 
  • In addition to the research.com honour, Dr. Hancock was also installed as a Fellow of the National Academy of Inventors (NAI) based in Tampa, Florida.
  • Dr. Hancock will be travelling to Washington, DC, on June 25, 2023, to accept his Fellowship at the NAI's annual meeting.
  • The Company's COO, Tim Murphy, commented, "The Asep board and team would like to congratulate Dr. Hancock for these prestigious honours.
  • Asep Inc. is very pleased to announce the addition of Louise Rose Pacini to the Company's advisory board, effective June 6, 2023.

Asep Inc. Announces Ground-breaking A.I. Technology for Rapid Identification of Severe Sepsis and Improved Superbug Therapies

Retrieved on: 
Saturday, June 3, 2023
The Lancet, ASEP, CSE, Hancock, University, Prevalence, Sepsis, Physician, Infection, COVID-19, TM, Risk assessment, FSE, St. Paul's Hospital, Biomarker, Dicarboxylic acid, Staphylococcus aureus, Sinusitis, Asep, Death, Hospital, Pandemic, Patient, Risk, Paul the Apostle, Artificial intelligence, Observation, Mortality, AI, ICU, Diagnosis, Bacteria, Health, FDA, UBC, Gene, Biofilm, Peptide, Chair, Medical device

Hancock, Killam Professor at the University of British Columbia (UBC), and analyzes the dysfunctional immune responses involved in sepsis to identify sets of genes that help assess whether a patient will acquire severe sepsis.

Key Points: 
  • Hancock, Killam Professor at the University of British Columbia (UBC), and analyzes the dysfunctional immune responses involved in sepsis to identify sets of genes that help assess whether a patient will acquire severe sepsis.
  • "We have harnessed AI to obtain practical outcomes in areas of high unmet medical need, including identifying severe sepsis cases.
  • Sepsis is a severe disease responsible for one in five deaths worldwide1 and essentially all deaths from severe COVID-19.
  • "Deciphering the underlying mechanisms of sepsis is key to risk assessment and devising novel treatments for sepsis," stated Hancock.